These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
381 related items for PubMed ID: 16365467
1. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S. Ann Intern Med; 2005 Dec 20; 143(12):857-69. PubMed ID: 16365467 [Abstract] [Full Text] [Related]
2. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Chen H, Suda KJ, Turpin RS, Pai MP, Bearden DT, Garey KW. Curr Med Res Opin; 2007 May 20; 23(5):1057-65. PubMed ID: 17519072 [Abstract] [Full Text] [Related]
3. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections. Masterton RG, Casamayor M, Musingarimi P, van Engen A, Zinck R, Odufowora-Sita O, Odeyemi IA. J Med Econ; 2013 Nov 20; 16(11):1344-56. PubMed ID: 24003830 [Abstract] [Full Text] [Related]
4. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Zilberberg MD, Kothari S, Shorr AF. Crit Care; 2009 Nov 20; 13(3):R94. PubMed ID: 19545361 [Abstract] [Full Text] [Related]
5. Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit. Pagès A, Iriart X, Molinier L, Georges B, Berry A, Massip P, Juillard-Condat B. Value Health; 2017 Dec 20; 20(10):1319-1328. PubMed ID: 29241891 [Abstract] [Full Text] [Related]
6. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Wingard JR, Wood CA, Sullivan E, Berger ML, Gerth WC, Mansley EC. Clin Ther; 2005 Jun 20; 27(6):960-9. PubMed ID: 16117996 [Abstract] [Full Text] [Related]
15. Comparison of caspofungin and amphotericin B for invasive candidiasis. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J, Caspofungin Invasive Candidiasis Study Group. N Engl J Med; 2002 Dec 19; 347(25):2020-9. PubMed ID: 12490683 [Abstract] [Full Text] [Related]
16. Caspofungin: a review of its use in the treatment of fungal infections. McCormack PL, Perry CM. Drugs; 2005 Dec 19; 65(14):2049-68. PubMed ID: 16162025 [Abstract] [Full Text] [Related]
17. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA. J Acquir Immune Defic Syndr; 2002 Oct 01; 31(2):183-7. PubMed ID: 12394797 [Abstract] [Full Text] [Related]